Application of human amniotic epithelial cells in regenerative medicine: a systematic review

Qiuwan Zhang and Dongmei Lai

Abstract

Human amniotic epithelial cells (hAECs) derived from placental tissues have gained considerable attention in the field of regenerative medicine. hAECs possess embryonic stem cell-like proliferation and differentiation capabilities, and adult stem cell-like immunomodulatory properties. Compared with other types of stem cell, hAECs have special advantages, including easy isolation, plentiful numbers, the obviation of ethical debates, and non-immunogenic and non-tumorigenic properties. During the past two decades, the therapeutic potential of hAECs for treatment of various diseases has been extensively investigated. Accumulating evidence has demonstrated that hAEC transplantation helps to repair and rebuild the function of damaged tissues and organs by different molecular mechanisms. This systematic review focused on summarizing the biological characteristics of hAECs, therapeutic applications, and recent advances in treating various tissue injuries and disorders. Relevant studies published in English from 2000 to 2020 describing the role of hAECs in diseases and phenotypes were comprehensively sought out using PubMed, MEDLINE, and Google Scholar. According to the research content, we described the major hAEC characteristics, including induced differentiation plasticity, homing and differentiation, paracrine function, and immunomodulatory properties. We also summarized the current status of clinical research and discussed the prospects of hAEC-based transplantation therapies. In this review, we provide a comprehensive understanding of the therapeutic potential of hAECs, including their use for cell replacement therapy as well as secreted cytokine and exosome biotherapy. Moreover, we showed that the powerful immune-regulatory function of hAECs reveals even more possibilities for their application in the treatment of immune-related diseases. In the future, establishing the optimal culture procedure, achieving precise and accurate treatment, and enhancing the therapeutic potential by utilizing appropriate preconditioning and/or biomaterials would be new challenges for further investigation.

Keywords: Human amniotic/amnion epithelial cells, Cell transplantation, Differentiation, Paracrine properties, Immunomodulation, Regenerative medicine
Background

Human amniotic/amnion epithelial cells (hAECs) are derived from the innermost layer of the term placenta closest to the fetus, and they have been shown to have the potential to be seed cells for allogeneic cell therapies. Over the past 20 years, interest has been growing regarding the utility of hAECs in regenerative medicine due to their proliferative capacity, multilineage differentiation potential, ease of access, and safety. Advances in stem cell-based approaches have revealed that hAECs are perinatal stem cells that possess embryonic stem cell-like properties and the ability to be induced to differentiate. As promising seed stem cell, hAECs have been widely used to treat various diseases through transplantation therapy. Evidence supported by animal studies has revealed that hAECs show therapeutic potential for treatment of many diseases, including neurological disorders [1–4], lung injury [5, 6], liver injury [7], diabetes [8], acute kidney failure [9], cardiovascular diseases [10], wound healing [11], healing of stage III pressure ulcers [12], intrauterine adhesion [13], and premature ovarian failure (POF) [14]. Although hAECs have exhibited good therapeutic efficacy, they possess differences in differentiation potential, secretory function, and immunomodulatory activity under different conditions, producing specific effects depending on their application. In this review, we mainly examined the literature about the therapeutic potential of hAECs and summarized the different repair mechanisms in injured tissues and disorders; we also discussed the induced differentiation plasticity, homing and differentiation, paracrine function, and immunomodulatory capacity of hAECs. Finally, we described the current research strategies and proposed new prospects for hAEC-based clinical applications in the future.

Methods

Comprehensive literature searches using PubMed, MEDLINE, or Google Scholar were performed to identify articles for review written in English focusing on the biology of hAECs and the role of hAECs in injured tissues, diseases, and regenerative medicine.

Biological characteristics of hAECs

hAECs are obtained from the amniotic membrane of term placentas, which are discarded after birth. Thus, hAECs are readily available, require no invasive procedures for harvesting, and avoid relevant ethical issues. Isolated hAECs express surface markers of embryonic stem cells such as stage-specific embryonic antigen-3 and 4 (SSEA-3 and SSEA-4), octamer-binding transcription factor-4 (OCT-4), and tumor rejection antigen 1-60 and 1-80 (TRA1-60 and TRA1-80) [15]. Although hAECs possess stem cell-like characteristics, they do not exhibit unlimited proliferation due to the lack of telomerase activity and no risk of tumorigenesis in vivo [16]. Moreover, hAECs have tri-mesodermal lineage differentiation potential; they can produce osteogenic, adipogenic, and chondrogenic lineages under appropriate culture conditions [17]. Notably, hAECs have low expression levels of human leukocyte antigens (including HLA-A, HLA-B, and HLA-C and HLA-DR), which are key antigens involved in recipient rejection [1, 18]. A study confirmed that intravenous administration of hAECs did not result in hemolysis, allergic reactions, toxicity, or tumor formation, which demonstrated that hAECs were systematically safe [19]. Thus, hAECs are considered a promising source of stem cells for regenerative medicine.

To safely and effectively use hAECs to repair the function of injured tissues and treat diseases, it is essential that they are of high quality. Currently, the trypsin/EDTA technique is the most efficient for obtaining viable hAECs for subsequent culture [20, 21]. The key aspects involved in the isolation of hAECs with high yield, viability, and purity have been previously summarized [22]. Meanwhile, standard manufacturing and cryopreservation process were established that resulted in the isolation of highly purified hAECs with reproducible and high viability in accordance with current good manufacturing procedure (GMP) requirements [23]. In addition, a study found that epidermal growth factor (EGF) was a strong mitogen that promoted the proliferation of hAECs by regulating the cell cycle rather than inducing differentiation in the process of culture in vitro [24]. Although primary hAECs strongly expressed stemness-related genes for OCT-4, Sox-2, and Nanog, these gene expression levels gradually declined with an increase in passage number [25]. Study revealed that cultured hAECs underwent epithelial to mesenchymal transition (EMT) through the autocrine production of TGF-beta (TGF-β) [26]. Moreover, TNF-alpha (TNF-α) and matrix metalloproteinase (MMP) could induce EMT of hAECs [27]. Therefore, researchers have tried to explore different culture methods to maintain stemness and avoid EMT occurrence. A study found that hAECs were cultured in substitute serum medium (SSM) in which fetal calf serum (FCS) was replaced by knockout serum replacement (SR), contributing to maintain stem cell characteristics for up to 4 passages [28]. Furthermore, xenobiotic-free medium was used for the culture of hAECs to eliminate the effects of growth factors [29]. Meanwhile, a serum-free protocol established for hAEC isolation and culture resulted in better cell growth than that achieved by a traditional culture system with serum [19], which made the clinical applications of hAECs more feasible.
Although the biological characteristics of hAECS could be affected by the culture conditions and number of passages, they can be sufficiently expanded under certain culture conditions and maintain reproducible biological characteristics. Therefore, further understanding of the biological characteristics of hAECS and improvement of the isolation and culture techniques are important for applying hAECS in regenerative medicine.

**Induced differentiation plasticity of hAECS in vitro**

One study indicated that hAECS were more efficiently reprogrammed to assume a state of induced pluripotency than adult fibroblasts [30]. An increasing number of studies have found that hAECS display an extremely high level of differentiation plasticity in vitro following chemical induction, biological treatment, gene transfection, or coculture with other types of cells (Table 1).

A series of studies reported that hAECS were successfully induced to differentiate into hepatocyte-like cells through a combined approach using dexamethasone, hepatocyte growth factor (HGF), insulin-like growth factor (IGF), and other cytokines [31]; extracellular matrix proteins together with a mixture of growth factors, cytokines, and hormones or cocultured with mouse hepatocytes [32]; a specific hepatic differentiation protocol [33]; and four-step hepatic differentiation [34]. In addition, hAECS could respond to proangiogenic signals, form capillary-like structures, and differentiate into hepatic sinusoidal endothelial cells (HSECs) in vivo [35].

With regard to pancreatic cells, hAECS were induced to form three-dimensional (3D) spheroids and differentiate into insulin-producing cells by culturing them on an extracellular matrix [36]. When hAECS were treated with activin A or nicotinamide combined with the transcription factor pancreatic and duodenal homeobox-1 (PDX1), they differentiated into pancreatic lineage cells [37]. Furthermore, hAECS differentiated into islet-like cells expressing endocrine-related genes, including PDX1, insulin, and glucagon, as a result of the addition of nicotinamide plus betacellulin; importantly, the differentiated islet-like cells secreted high levels of insulin in response to high glucose exposure [38, 39]. In addition, the potential for the differentiation of hAECS into pancreatic cells triggered by overexpressing PDX1 could be strengthened with a mix of EGF and poly-L-ornithine in the culture environment [40]. A study showed that hAECS cocultured with submandibular gland acinar cells in a double-chamber system differentiated into acinar cells [41]. When hAECS were treated with nicotinamide and N2 supplement, they differentiated into insulin-secreting cells (ISCs) expressing PDX1 and beta2 microglobulin, meaning that they show potential for application to cell therapy of type I diabetes [42].

The fluid from specific tissues and organs could also affect the process of hAECS differentiation. It was confirmed that hAECS cultured with medium containing 5% human follicular fluid expressed the germ cell-specific markers GDF9 and DAZL [43], and formed a follicle-like structure [44]. By using serum substitute supplement (SSS) medium, hAECS were induced to differentiate into germ cells expressing DAZL, VASA, GDF9, and ZP3 [45].

The ability of hAECS to differentiate into corneal epithelial-like cells has been confirmed in many studies. For example, hAECS were induced to differentiate into corneal epithelial-like cells when they were cocultured with human corneal epithelial cells (hCECs) [46] and seeded onto rabbit corneal stroma [47] or by using culture media collected from spontaneously immortalized human corneal epithelial cells (S-ihCECs) to replicate the corneal epithelial microenvironment [48]. These methods may be suitable for the reconstruction of the corneal epithelium. Additionally, hAECS were able to differentiate into conjunctival epithelium-like cells with partial physiological function upon culture with induced-denuded conjunctival matrix and conjunctival homogenate [49].

The capability of hAECS to differentiate into neural cells was affected by factors including serum, noggin, basic fibroblast growth factor (bFGF), and retinoic acid [50]. A recent study showed that hAECS were induced to undergo neuronal differentiation by treatment with rosmarinic acid [51]. hAECS differentiated into cortical progenitor lineage cells and showed a cortical neuron phenotype when treated with growth factors and small molecules [52]. Additionally, hAECS were induced to differentiate into Schwann-like cells (SCs) that exhibited the morphological, phenotypic, and functional characteristics of SCs when they were treated according to a coculture approach [53].

Osteogenic differentiation of hAECS was induced by the upregulation of Runx2, osterix, alkaline phosphatase (ALP), collagen I, and osteopontin (OPN) in vitro [54]. hAECS treated with either bone morphogenetic protein (BMP)-7 or TGF-β1 expressed cartilage markers, including aggrecan, Sox-9, CEP-68, and type II and X collagens [55]. Interestingly, the osteogenic differentiation of hAECS was also induced by mechanical stretching [56], which means that changing the physical conditions may be a new approach to affect the process of hAEC differentiation.

Additionally, hAECS could form 3D structures and express the cystic fibrosis transmembrane conductance regulator (CFTR) by adding small airway growth medium (SAGM) [57]. When treated with activin A and BMP-4, hAECS were able to express cardiac-specific genes, including Nkx2.5 and alpha-actinin, indicating
Table 1 The induced differentiation of hAECs in vitro

| Organ/focuses | Cell types | Phenotypes | Inducing conditions | References |
|---------------|------------|------------|---------------------|------------|
| Liver         | Hepatocyte-like cells | Expressing hepatocyte-like cell functional genes: albumin, CYP1A1, CYP1A2, c-met, and transcription factors: HNF3, HNF4, C/EBPa, and HNF1 | Using a combined approach of dexamethasone, HGF, IGF, and other cytokines | [31] |
|               | Hepatocyte-like cells | Expressing hepatic related genes: albumin, A1AT, CYP3A4, 3A7, 1A2, 2B6, and the asialoglycoprotein receptor 1 (ASGPR1) | Using extracellular matrix substrates; cocultured with mouse hepatocytes | [32] |
|               | Hepatic differentiation | Displayed a similar hepatic morphology; expressing specific hepatic genes: albumin, CYP7A1, and CYP3A4 | Using a specific hepatic differentiation protocol | [33] |
|               | Hepatic differentiation | The formation of bile canaliculi; secreting albumin; uptaking low-density lipoprotein and showing inducible CYP3A4 and CYP2C9 enzymatic activities | Using four-step hepatic differentiation protocol | [34] |
|               | Hepatic sinusoidal endothelial cells | Forming capillary-like structure in vitro and differentiate into HSECs in vivo | Under proangiogenic conditions | [35] |
| Pancreas      | Insulin-producing cells | The formation of three-dimensional (3D) spheroids; producing pancreatic endocrine hormones; releasing C-peptide under hyperglycemic condition | Culturing on extracellular matrix | [36] |
|               | Pancreatic lineage cells | Expressing pancreatic endoderm and progenitor genes: NKX6.1, NeuroD1, and pancreatic lineage genes: PDX1, SOX17, RXF6 | Combination of transcription factor PDX1 with activin A or nicotinamide | [37] |
|               | Islet-like cells | Expressing the endocrine-related genes: PDX1, ngn3, insulin, and glucagon; secreting insulin in response to high glucose exposure | Using DMEM with different supplements and suspension culture | [38] |
|               | Islet-like cell clusters | Expressing pancreatic development-related genes: PDX1, NKX6-1, NEUROG3, PAX6, INS, and GCC; insulin positive and sensitive to glucose | Adding nicotinamide plus betacellulin | [39] |
|               | Pancreatic cells | Expressing pancreatic differentiation related genes: NKX6.1, SOX17, RXF6, NEUROD1, and PAX4 | Inducing endogenous PDX1 expression, EGF, and poly-L-ornithine | [40] |
|               | Acinar cells | Expressing o-amylase and mucins | Cocultured with submandibular gland acinar cells using a double-chamber system | [41] |
|               | Insulin secreting cells | Expressing PDX1 and beta2 microglobulin; secreting insulin | Treated with nicotinamide and N2 supplement | [42] |
| Ovary         | Germ cell-like cells | Expressing germ cell-specific genes: GDF9, DAZL, and SCP3; producing estradiol | Medium supplemented with 5% human follicular fluid | [43] |
|               | Follicle-like structure | Expressing germ cell-specific genes DAZL and GDF9; secreting estradiol | Medium supplemented with 5% human follicular fluid | [44] |
|               | Germ cell-like cells (diploid cells) | Expressing germ cell-specific protein DAZL, oocyte-specific proteins GDF9 and ZP3, meiosis-specific proteins DMC1 and SCP3 | Cultured in medium containing serum substitute supplement (SSS) | [45] |
that hAECs have the potential to differentiate into cardiomyocytes [58]. In addition, the air-liquid interface could stimulate the early differentiation of hAECs into epidermal cells, which indicates their potential use for skin regeneration [59].

Taken together, these studies indicate that hAECs have strong potential to be induced to differentiate via changes in culture conditions and methods. Inducing the differentiation of hAECs toward a desired phenotype in vitro before injection or transplantation will be an effective method for replacing damaged cells for tissue regeneration.

### Homing and differentiation of hAECs in vivo

In addition to culture conditions, the differentiation potential of hAECs largely depends on the specific organizational microenvironment in vivo following transplantation. Grafted hAECs could migrate to injured tissue and further differentiate into the appropriate cell type under different conditions. Extensive animal studies have confirmed the capacity of hAECs to differentiate into essential and specialized cell types, which participate in the functional recovery of damaged tissues (Table 2).

Generally, the initial presence of injury or damage causes early cell death and loss of functional cells, and then a series of secondary reactions occur, including hypoxia, inflammation, ischemia, and dysfunction. Study reported that hAECs not only expressed specific markers of nerve cells, but also migrated along nerve fibers in the corpus callosum [69]. A series of studies demonstrated that hAECs exerted neuroprotective effects, possibly in

### Table 1 The induced differentiation of hAECs in vitro (Continued)

| Organ/focuses | Cell types                  | Phenotypes                                                                 | Inducing conditions                                                                 | References |
|---------------|-----------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------|
| Eyes          | Corneal epithelial-like cells showing a similar morphology to hCECs; expressing CK3/12, CK14, CK19, and P63 | Cultured with human corneal epithelial cells (hCECs) in a Transwell coculture system | [46]       |
|               | Corneal epithelial-like cells expressing CK3/12 | Seeded onto rabbit corneal stroma                                           | [47]       |
|               | Corneal epithelial-like cells expressing CK3/12 | Adding the conditioned medium of spontaneously immortalized human corneal epithelial cells (S-ihCECs) | [48]       |
|               | Conjunctival epithelium-like cells showed conjunctival epithelium phenotype; producing musac | Cultured with induced-denuded conjunctival matrix and conjunctival homogenate | [49]       |
| Nervous system | Neuronal differentiation expressing neural cell markers NSE and NeuN | Adding noggin, bFGF, and retinoic acid                                       | [50]       |
|               | Neuronal differentiation upregulation of transcription factors involving in neuronal differentiation | Treated with rosmarinic acid                                                   | [51]       |
|               | Cortical progenitors expressing cortical neuron-specific proteins: TBR2, OTX2, NeuN, and β-III-tubulin | Adding growth factors and small molecules                                      | [52]       |
|               | Schwann-like cells exhibiting a typical bipolar or tripolar morphology; expressing S-100; increasing the expressions of BDNF and GDNF | Cocultured with Schwann cells (SCs)                                             | [53]       |
| Bone          | Osteogenic differentiation increasing cellular ALP activity and extracellular mineralization; expressing Runx2, osterix, ALP, collagen 1, and OPN | Cultured with classic osteogenic medium                                         | [54]       |
|               | Cartilage differentiation expressing cartilage markers: aggrecan, Sox9, CEP-68, and type II and X collagens; promoting matrix synthesis | Treated with BMP-7 or TGF-β1                                                     | [55]       |
|               | Osteoblasts upregulating Runx2, ALP, and OPN | Mechanical stretch                                                             | [56]       |
| Respiratory   | Polarized airway-like cells forming 3D structures; expressing CFTR and possessing functional iodide/chloride (I−/Cl−) ion channels | Cultured with small airway growth medium (SAGM)                               | [57]       |
| Heart         | Cardiomyocyte-like cells expressing cardiac-specific genes Nkx2.5 and alpha-actinin | Treated with activin A and BMP-4                                                | [58]       |
| Skin          | Epidermal cells the presence of desmosomes; expressing CK18 and CK14 | Cultured in air-liquid interface                                               | [59]       |
relation to neuronal differentiation. In a Parkinson’s disease (PD) model, hAECs migrated to and survived in the injured striatum, and partially ameliorated apomorphine-induced rotational asymmetry through differentiating into TH-immunoreactive cells [60]. Another study found that grafted hAECs migrated to the injured brain area via a CXC chemokine receptor type 4 (CXCR4)-dependent mechanism in ischemic stroke [70], and chemokines released by damaged tissues were a key mediator of transplanted stem cell tracking to the site of injury [71]. In ischemic brain injury, grafted hAECs migrated into the ischemic area and expressed the neuronal specific marker (MAP 2) and neuronal progenitor marker (Nestin), and they significantly ameliorated behavioral dysfunction and reduced infarct volume [61]. In transgenic mice with Alzheimer’s disease (AD), transplanted hAECs survived for at least 8 weeks, and they were shown to migrate to the third ventricle without immune rejection and to express the stem cell markers OCT-4 and Nanog [62]. In thioacetamide-induced chronic liver failure, engrafted hAECs migrated into the liver and differentiated into functional hepatocyte-like cells, improved the state of the liver following chronic injury, and produced a high level of serum albumin [34]. In addition, transplanted hAECs differentiated into type I and II alveolar cells and mitigated ventilation-induced preterm lung injury [63]. In chemotherapy-induced POF, grafted hAECs were shown to migrate to the injured ovaries and differentiate into granulosa cells to restore folliculogenesis and ovarian function [64]. In myocardial infarction, hAECs improved cardiac function following transplantation by differentiating into cardiomyocyte-like cells [65]. In gland injury induced by radiation, hAECs in the recipient glands differentiated into acinar-like cells, resulting in morphological and functional restoration of the salivary gland [66]. Additionally, transplanted hAECs could express connexin 26 and Na-K-adenosine triphosphatase in the inner ear [67]. In Achilles tendon injury, hAECs remained

| Diseases/focuses | Transplantation method/dose | Species | Outcome | Repair mechanism | References |
|-----------------|-----------------------------|---------|---------|------------------|-----------|
| Parkinson’s disease | Injection of striatum (4 × 10^4 cells) | Rats | Ameliorating of apomorphine-induced rotational asymmetry | Differentiating into TH-immunoreactive cells | [60] |
| Ischemic brain injury | Injection of dorsolateral striatum (8 × 10^5 cells) | Rats | Ameliorating behavioral dysfunction; reducing infarct volume | Expressing neuronal progenitor marker (Nestin), neuronal marker (MAP 2), astrocyte marker (GFAP) | [61] |
| Alzheimer’s disease | Intracerebroventricular injection (1.2 × 10^6 cells) | Mice | Improving the spatial memory; increasing acetylcholine concentration and the number of hippocampal cholinergic neurons | Expressing stem cell-specific markers OCT-4 and Nanog | [62] |
| Chronic liver failure | Intrasplenic injection (2 × 10^6 cells) | Mice | Liver was larger in size, softer, and less nodular; increasing serum albumin level | Differentiating into functional hepatocytes positive for albumin | [34] |
| Lung injury | Fetal jugular vein (3 × 10^6 cells) | Sheep | Reducing ventilation-induced preterm lung injury, including less collagen, elastin, fibrosis, normalized secondary-septal crests | Differentiating into type I and II alveolar cells | [63] |
| Premature ovarian failure | Intravenously injection (2 × 10^6 cells) | Mice | Promoting folliculogenesis; repairing ovarian function | Differentiating into granulosa cells expressing follicle-stimulating hormone receptor (FSHR) | [64] |
| Myocardial infarction | Injection of the infarcted myocardium (1 × 10^6 cells) | Rats | Decreasing infarct size; improving cardiac function | Differentiating into cardiomyocyte-like cells expressing myocardium-specific marker myosin heavy chain | [65] |
| Gland injury | Intra-glandular injection (1 × 10^5 cells) | Mice | Restoring the morphology and function of salivary gland | Differentiating into acinar-like cells | [66] |
| Inner ear injury | Injection of cochlea (1 × 10^5 cells) | Hartley guinea pigs | Cooperation in the regional potassium ion recycling | Expressing cochlear fibrocyte markers connexin 26 and Na-K-adenosine triphosphatase | [67] |
| Achilles tendon injury | In situ injection (10 × 10^6 cells) | Sheep | Improving tendon microarchitecture and blood vessel remodeling; contributing to tendon regeneration | Differentiating into tenocytes expressing collagen I | [68] |
viable within the host tendons and established an active dialogue with endogenous progenitor cells, and the differentiated hAECs displayed a tenocyte-like phenotype and contributed to the recovery of the function of Achilles tendon [68].

Although numerous studies have demonstrated that hAECs can migrate and differentiate into the desired type of cells to replace damaged cells, only a few studies have reported the long-term functional integration of engrafted hAECs in target organs. The limited homing efficiency and the lack of long-term cell tracking approaches could be major reasons for the lack of functional research on differentiated cells. In addition to the efficacy of engraftment, several additional factors for hAEC therapy need to be considered, including the number of administered cells, the route of infusion, and the biodistribution of cells post-transplantation. Although tail vein injection is the most widely used transplantation method to deliver cells into a host, most engrafted cells are trapped in the lungs rather than the target organs. For example, splenic injection was a more efficient route of administration of hAECs for targeting the liver than tail vein infusion [72, 73]. Therefore, selecting an appropriate transplantation route is vital for cell survival, differentiation of grafted cells, and the recovery of function.

Therefore, transplanted hAECs can be recruited to damaged tissues and exert differentiation plasticity in vivo based on the specific types of cells needed for replacement therapy to treat many diseases.

Paracrine potential of hAECs

Migration of grafted hAECs to injured tissues and replacement of damaged cells are thought to be the mechanisms behind the alleviation of acute and chronic injury; however, there are several obstacles to cell transplantation, such as poor survival and limited restoration ability. Currently, accumulating evidence has demonstrated that hAECs can provide a beneficial microenvironment for cell survival and activate endogenous mechanisms of tissue regeneration by secreting bioactive cytokines and microvesicles. This is supported by evidence that the injection of the conditioned media of hAECs (hAEC-CM) could achieve a positive outcome similar to that of cell transplantation, representing an acceptable alternative for stem cell-free biotherapy. As early as 2000, a study showed that hAECs could synthesize and release brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF), which play important roles in the early stages of neural development in the embryo as well as the neuroprotective effect [74, 75]. Moreover, study also showed that hAECs secreted considerable amounts of proangiogenic, anti-fibrotic, and anti-inflammatory factors, including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), angiogenin (AGN), and insulin-like growth factor (IGF) [76]. The therapeutic function of these bioactive secretory factors in various disease models has been studied and confirmed (Table 3).

For example, hAECs enhanced the survival of dopamine (DA) neurons by producing biologically activated neurotrophins, such as BDNF and NT-3, and they counteracted the loss of DA neurons in PD model mice [60, 77]. In corneal injury, hAEC-CM injection promoted corneal wound healing by reducing the infiltration of inflammatory cells [78] and reducing corneal neovascularization [79]. hAEC-CM injection protected ovaries against chemotherapy-induced damage, enhanced the ovarian microenvironment, and promoted ovarian vessel formation [80]. Further study found that hAEC-secreting TGF-β1 played important roles in protecting granulosa cells against apoptosis [81]. On the other hand, study has shown that hAECs suppressed collagen production in human hepatic stellate cells through the paracrine pathway [89], and some important soluble factors such as MMP-2 and MMP-9 secreted by hAECs played vital roles in anti-fibrosis and promoting extracellular matrix (ECM) remodeling, especially in liver injury and fibrosis models [7, 82]. In a diet-induced murine non-alcoholic steatohepatitis (NASH) model, administration of hAEC-CM reduced liver fibrosis and hepatic inflammation, supporting the anti-fibrotic properties of hAEC-CM [83]. Although hAECs have been reported to secrete angiogenic factors, including EGF, VEGF, AGN, and platelet-derived growth factor B (PDGFB), there have been some contradictory reports on their angiogenic effects to date. A study revealed that significantly different protective effects were exerted by term and preterm hAECs in vivo [90], which was related to the differences in the angiogenic ability of hAECs isolated from different gestational stages [91]. In addition, the impact of hAECs on angiogenesis could be influenced by the presence of inflammation in injured tissue [91]. Study found that hAECs under hypoxic condition could secrete the high levels of the human-origin proangiogenic cytokines, contributing to myocardial tissue regeneration [10]. Thus, the impact of microenvironmental biological cues on the paracrine function of transplanted hAECs should be considered to identify the optimal times for cell administration.

In addition, microvesicles or exosomes, as essential components of the hAEC paracrine pathway, have attracted much attention. Exosomes are small secretory vesicles that are involved in intercellular communication via the transport of bioactive cargo, including proteins, mRNA, microRNAs (miRNAs), and organelles [92]. Importantly, study has demonstrated that exosomes released by stem cells can effectively transport proteins, mRNAs, and miRNAs to exert a variety of effects on target tissues [93]. It has been shown
that hAEC-derived exosomes (hAEC-exosomes) promoted the migration and proliferation of fibroblasts, downregulated collagen expression, and improved skin wound healing by inducing the formation of well-organized collagen fibers in rats [84, 85]. Further study indicated that the effects of hAEC-exosomes were abolished by pretreating hAEC-exosomes with RNaseA, which indicates that miRNAs carried by exosomes play important roles in promoting wound healing [86]. In bleomycin-induced lung injury, hAEC-exosome transplantation reduced inflammation and fibrosis, and improved the tissue-to-airspace ratio by increasing macrophage phagocytosis, reducing neutrophil myeloperoxidase activity, and directly suppressing T cell proliferation. Further analysis found that some specific proteins comprising the cargo of hAEC-exosomes were mainly enriched in the MAPK signaling, apoptotic, and developmental biology pathways; however, the miRNAs were enriched in the PI3K-Akt, Ras, Hippo, TGF-β, and focal adhesion pathways [87]. Moreover, study also showed that proteins in hAEC-derived extracellular vesicles (hAEC-EVs) exerted anti-fibrosis function via modulating collagen synthesis and macrophage polarization in chronic liver fibrosis [82]. In addition, the target genes of miRNAs in hAEC-exosomes were mainly enriched in the phosphatidylinositol signaling system, PPAR signaling pathway, and apoptotic process pathway, which are involved in ovarian functional recovery mediated by hAEC-exosome transplantation [88].

Table 3 Paracrine function of hAECs in different diseases

| Diseases/focuses | Injection method | Species | Outcome | Repair mechanism | References |
|------------------|-----------------|---------|---------|------------------|------------|
| Parkinson’s disease | Injection of tegmentum of the midbrain | Rats | Enhancing the survival of DA; protecting the morphological integrity of TH-positive neurons against toxic insult | hAEC-CM (neurotrophins such as BDNF and NT-3) | [77] |
| Corneal alkali injury | Injection the dorsal bulbar subconjunctival | Rabbits | Reducing the infiltration of inflammatory cells; promoting corneal wound healing | hAEC-CM (anti-inflammatory factors) | [78] |
| Corneal injury | Topically application | Mice | Reducing corneal neovascularization; suppressing corneal inflammatory reactions | hAEC-CM (anti-inflammatory factors) | [79] |
| Premature ovarian failure | Intraperitoneally injection | Mice | Promoting the formation of vascular; restoring ovarian function | hAEC-CM (proangiogenic factors) | [80] |
| Premature ovarian failure | Ovarian injection | Mice | Promoting follicular development; inhibiting granulosa cell apoptosis; restoring ovarian function | hAEC-CM (TGF-β1; anti-apoptotic effect) | [81] |
| Chronic liver fibrosis | Intravenously injection | Mice | Reducing collagen synthesis and macrophage infiltration; inducing macrophage toward M2 phenotype | hAEC-CM (anti-fibrosis, anti-inflammation) | [82] |
| Non-alcoholic steatohepatitis | Intraperitoneally injection | Mice | Reducing hepatic inflammation; inhibiting liver fibrosis | hAEC-CM (anti-inflammation; anti-fibrosis) | [83] |
| Myocardial infarction | Cardiac injection | Rats | Regenerating myocardial tissue; improving cardiac function | hAEC-secreting proangiogenic factors | [10] |
| Wound healing | Topically injection | Rats | Promoting the migration and proliferation of fibroblasts; accelerating wound healing; inhibiting scar formation | hAEC-exosomes | [84, 85] |
| Wound healing | Topically injection | Mice | Stimulating the migration and proliferation of fibroblasts; accelerating wound healing | hAEC-exosomes (miRNAs) | [86] |
| Idiopathic pulmonary fibrosis | Intravenously injection; intranasal instillation | Mice | Reducing lung inflammation and fibrosis; improving tissue-to-airspace ratio | hAEC-exosomes (anti-inflammation; anti-fibrosis) | [87] |
| Chronic liver fibrosis | Intravenously injection | Mice | Reducing collagen synthesis and macrophage infiltration; inducing macrophage toward M2 phenotype | hAEC-EV (anti-fibrotic proteins) | [82] |
| Premature ovarian failure | Ovarian injection | Mice | Inhibiting the apoptosis of granulosa cells; repairing ovarian function | hAEC-exosomes (miR-1246; anti-apoptosis) | [88] |
of stem cell transplantation. Thus, exploring and identifying the most effective secretome components, including bioactive factors and extracellular vesicles/exosomes secreted by hAECs, will provide new treatment strategies for regenerative medicine.

**Immunomodulatory properties of hAECs**

In addition to the differentiation ability and paracrine function of hAECs, their powerful immunomodulatory properties also make their use in regenerative medicine a more reasonable option than the use of other cell types. Many studies have demonstrated that hAECs and hAEC-CM exert multiple immunosuppressive activities and anti-inflammatory properties. For example, hAECs suppressed both specific and non-specific T cell proliferation, decreased pro-inflammatory cytokine production, and inhibited the activation of stimulated T cells in vitro [94]. Furthermore, hAECs prevented monocyte-derived dendritic cell differentiation via cell-to-cell contact [95]. In addition, hAECs could produce a variety of immunoregulatory factors, including migration inhibitory factor (MIF), TGF-β, interleukin-10 (IL-10), and prostaglandin E2 (PGE2), contributing to suppress the function of inflammatory cells [96]. When hAECs were cocultured with peripheral blood mononuclear cells (PBMCs) derived from patients with unexplained recurrent spontaneous abortion, the proliferation of naïve CD4 T cells was significantly inhibited, and the production of Th1 and Th17 cytokines was reduced [97, 98]. hAECs significantly attenuated the level of oxidative burst of neutrophils in coculture system [99]. Additionally, hAEC-CM inhibited the chemotactic activity of neutrophils and reduced the proliferation of both T and B cells after mitogenic stimulation [100].

These immunomodulatory properties have laid the foundation for the use of these cells in treating inflammatory and immune-based diseases, and encouraging results have been obtained in different disease models (Table 4). In ischemic stroke, hAEC transplantation significantly reduced inflammation, leading to the recovery of brain function [70] and the improvement of brain function after intracerebral hemorrhage (ICH) by reducing microglial activation and producing anti-inflammatory factors [101]. In perinatal brain injury, hAEC transplantation reduced apoptosis and astrocyte areal coverage in the white matter, and increased the density of total and activated microglia via the release of trophic factors [102]. Moreover, hAECs mitigated fetal brain inflammation and reduced white matter injury via anti-inflammatory effects in the preterm ovine fetus, and they reduced the number of activated microglial cells in the white matter after repeated endotoxin exposure [103] and lipopolysaccharide (LPS)-induced intrauterine inflammation [104]. In multiple sclerosis, splenocytes from hAEC-treated mice showed a Th2 cytokine shift with significantly elevated interleukin-5 (IL-5) production [105]. In lung injury, a series of studies demonstrated that transplanted hAECs repaired lung function by decreasing macrophage and neutrophil infiltration, fibrosis, and collagen content; importantly, hAECs required normal host macrophage function to exert their reparative effects [106]. Further study showed that hAECs mediated lung function recovery by modulating macrophage recruitment and polarization in a paracrine manner [107]. Moreover, hAECs induced the maturation of non-Tregs into FoxP3-expressing Tregs mediated by TGF-β. Tregs are required for hAEC-mediated macrophage polarization and lung function recovery [108]. Another study also showed that the immunomodulatory effects of hAECs on macrophage phagocytic activity and T cell suppression are lipoxin-A4 (LXA4) dependent [109]. In addition, hAECs modulated the pulmonary inflammatory response to ventilation in preterm neonatal lambs and reduced acute lung injury [110]. Other studies reported that leukocyte infiltration of the lungs was not reduced by hAECs; however, the levels of inflammatory cytokines were reduced in intrauterine inflammation-induced lung injury [111] and in hyperoxia-induced neonatal lung injury [112]. Moreover, hAECs reduced the number of macrophages, dendritic cells, and natural killer cells and improved the tissue-to-airspace ratio and septal crest density in neonatal lung injury in a dose-dependent manner, regardless of the route of administration [113]. In early Achilles tendon defects, hAECs inhibited inflammatory cell infiltration, activated M2 macrophage subpopulation recruitment, and accelerated blood vessel and extracellular matrix remodeling by secreting immunoregulatory factors [68]. hAECs restored ovarian function by directly upregulating Treg cells in the spleen and reducing the inflammatory reaction in injured ovaries by modulating the polarization and function of macrophages in a paracrine manner [114]. In mice with experimental autoimmune thyroiditis (EAT) and systemic lupus erythematosus (SLE), hAECs prevented lymphocyte infiltration into the thyroid and improved thyroid follicular function by reducing the Th17/Treg cell ratio and increasing the proportion of B10 cells [115]. In addition, grafted hAECs accelerated diabetic wound healing and granulation tissue formation, partially by inducing differentiation of macrophages toward an M2 phenotype and promoting neovascularization in a paracrine manner [116]. In liver injury, hAECs induced the differentiation of macrophages toward an M2 phenotype, which was associated with a reduction in established hepatic fibrosis [117].

These immune remodeling processes, which are mediated by hAECs and soluble factors and extracellular vesicles secreted by hAECs, are of substantial importance to the regenerative process. Thus, hAECs have emerged as
valid candidates for potential use in treating inflammatory and immune-based disorders.

**Clinical trials of hAEC transplantation**

On the basis of the preclinical animal studies mentioned above, a series of clinical trials to assess the safety and effectiveness of hAEC transplantation in the treatment of various diseases have been registered at [http://ClinicalTrials.gov](http://ClinicalTrials.gov) and are being conducted (Table 5).

Researchers conducted an early phase 1 clinical trial of hAEC transplantation in patients with intrauterine adhesion. Changes in the endometrial thickness, menstrual

| Diseases/focuses | Transplantation method/ dose | Species | Outcome | Repair mechanism | References |
|------------------|-----------------------------|---------|---------|------------------|------------|
| Ischemic stroke  | Tail vein injection (1 × 10^6 hAECs); saphenous vein injection (5 × 10^6 hAECs) | Mice, marmosets | Reducing brain infarcted volume and functional deficits; promoting long-term functional recovery | Inhibiting apoptosis and inflammation; modulating immunosuppression | [70] |
| Intracerebral hemorrhage | Injection of cortex (1 × 10^6 hAECs) | Rats | Reducing brain edema; ameliorating the neurologic deficits | Suppressing the activation of microglia; reducing the inflammatory response | [101] |
| Perinatal brain injury | Intravenously (1 × 10^5 hAECs) | Mice | Reducing microglia apoptosis; increasing microglial phagocytic activity | Modulating microglia via releasing trophic factors | [102] |
| Fetal brain injury | Injection of brachial artery catheter (6 × 10^6 hAECs) | Ewes | Reducing white matter injury; mitigating associated brain injury | Inhibiting inflammation and apoptosis; reducing the number of activated microglial cells | [103, 104] |
| Multiple sclerosis | Intravenously (2 × 10^6 hAECs) | Mice | Reducing monocyte/macrophage infiltration and demyelination | Mediating immunosuppression via secreting TGF-β and PGE2; promoting Th2 cytokine shift | [105] |
| Lung injury | Intraperitoneally (4 × 10^6 hAECs) | Mice | Decreasing neutrophil infiltration, fibrosis, collagen content; repairing lung function | Depending on the function of host macrophage | [106] |
| Lung injury | Intraperitoneally (4 × 10^6 hAECs) | Mice | Reducing macrophage infiltration; increasing the number of M2 macrophage | Modulating macrophage polarization, migration, and phagocytosis via paracrine pathway | [107] |
| Lung injury | Intraperitoneally (4 × 10^5 hAECs) | Mice | Mitigating lung inflammation and fibrosis | Tregs are required for hAEC-mediated macrophage polarization | [108] |
| Lung injury | Intraperitoneally (4 × 10^5 hAECs) | Mice | Reducing pro-inflammatory immune cells; preventing lung injury | Mediating immunomodulation partly through LXA4 | [109] |
| Preterm neonatal lung injury | Intratracheally (90 × 10^6 hAECs) | Lambs | Modulating the pulmonary inflammatory response to ventilation; reducing acute lung injury | Immunomodulatory effects | [110] |
| Fetal lung injury | Fetal jugular vein injection (90 × 10^6 hAECs); fetal intratracheal infusion (18 × 10^6 hAECs) | Sheep | Attenuating the fetal pulmonary inflammatory response | Reducing inflammatory cytokines | [111] |
| Neonatal lung injury | Intraperitoneally (4.5 × 10^6 hAECs) | Mice | Partially reducing hypoxia-induced inflammation and structural lung damage | Attenuating inflammation | [112] |
| Neonatal lung injury | Intravenously; intratracheal infusion (5 × 10^5; 7.5 × 10^5; 1 × 10^6 hAECs) | Mice | Improving the tissue-to-airspace ratio and the long-term of cardiorespiratory function | Reducing macrophages, dendritic cells, and natural killer cells | [113] |
| Achilles tendon injury | In situ filling (10 × 10^6 hAECs) | Sheep | Inhibiting inflammatory cell infiltration; activating the M2 macrophage subpopulation | Regulating inflammatory and immunomodulatory response; accelerating blood vessel and ECM remodeling | [68] |
| Autoimmune ovarian disease | Intravenously (2 × 10^6 hAECs) | Mice | Restoring ovarian function; upregulating Treg cells; reducing the inflammatory reaction | Modulating macrophage function by paracrine factors (TGF-β and MIF) | [114] |
| Experimental autoimmune thyroiditis; systemic lupus erythematosus | Intravenously (1.5 × 10^6 hAECs); intravenously (1.5 × 10^6 hAECs) | Mice | Preventing lymphocyte infiltration into the thyroid; improving the damage of thyroid follicular; reducing immunoglobulin profiles | Modulating the immune cell balance by downregulating the ratios of Th17/Treg cells; upregulating the proportion of B10 cells | [115] |
| Diabetic wound healing | Intradermally (1 × 10^6 hAECs) | Mice | Promoting diabetic wound healing | Reducing inflammation and promoting neovascularization by paracrine pathway | [116] |
| Liver injury | Intravenously (2 × 10^6 hAECs) | Mice | Reducing hepatic fibrosis | Inducing M2 macrophage phenotype | [117] |
Table 5: Clinical trials of hAECs transplantation registered at ClinicalTrials.gov

| Study | Disease Description | Disease | Design | Start date | Status | Phase | Estimated enrollment | Intervention | ClinicalTrials.gov identifier |
|-------|---------------------|---------|--------|------------|--------|-------|----------------------|--------------|-------------------------------|
| 1     | Human Amniotic Epithelial Cell in Treatment of Refractory Severe Intrauterine Adhesion | Intrauterine adhesion | Safety and effectiveness | March 2018 | Not yet recruiting | 1 | 20 | Uterine cavity infusion (100 million) | NCT03381807 |
| 2     | Human Amniotic Epithelial Cells for Asherman’s Syndrome | Asherman’s syndrome | Safety and effectiveness | October 2017 | Not yet recruiting | 1 | 50 | Biological amnion; biological amnion loaded with hAECs (100 million); intravenous infusion (100 million); intrauterine infusion (100 million); hydrogel loaded with hAECs (100 million) | NCT03223454 |
| 3     | A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Insufficiency Patients | Primary ovarian insufficiency/pregnancy ovarian failure/infertility | Safety and effectiveness | June 2020 | Recruiting | 1 | 36 | Bilateral ovarian artery infusion (2 × 10^7 cells) | NCT02912104 |
| 4     | Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency | Premature ovarian failure | Safety and effectiveness | December 2017 | Not yet recruiting | Not applicable | 20 | Minimally invasive implantation (200 million); intravenous infusion (100 million for 3 times) | NCT03207412 |
| 5     | Human Amniotic Epithelial Cells for Treatment of Bronchial Fistula | Bronchial fistula | Therapeutic potential | October 2016 | Recruiting | 1 | 10 | Endoscopic injection of hAECs to fistula (3–5 × 10^7 cells) | NCT02959333 |
| 6     | Effect of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy | Spastic cerebral palsy | Therapeutic potential | April 2017 | Enrolling by invitation | 1 | 10 | Intrathecal injection | NCT03107975 |
| 7     | Treatment of Non-union of Limb Fracture with Human Amniotic Epithelial Cells (hAECs) | Non-union fracture | Safety and efficacy | December 2017 | Not yet recruiting | 1/2 | 36 | Transplant to non-union site (50 million) | NCT03031509 |
| 8     | hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation | Leukemia | Observational | July 2020 | Recruiting | Not applicable | 30 | Unknown | NCT03759899 |
| 9     | Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation | Acute graft-versus-host disease | Safety and efficacy | July 2020 | Recruiting | Not applicable | 27 | Infusion of hAECs (1 × 10^7, 2 × 10^7, 5 × 10^7 cell/kg) | NCT03764228 |

Blood volume, and pregnancy rate will be observed to evaluate the safety and effectiveness of hAECs for treating intrauterine adhesion (NCT03381807). Another similar study was designed and conducted by using different interventional treatments with amnion, amnion loaded with hAECs, intravenous or intrauterine infusion of hAECs, and hydrogel loaded with hAECs to observe the therapeutic safety and effectiveness of...
hAECs in patients with intraterine adhesion (NCT03223454).

Our research team designed and conducted a phase 1 clinical trial to evaluate the safety and effectiveness of bilateral ovarian artery infusion of hAECs into patients with POF. To date, we have recruited subjects and completed two trials of hAEC treatment in POF patients, and the results showed that hAEC transplantation increased the levels of estrogen and AMH, decreased FSH levels, and alleviated clinical symptoms (NCT02912104). Another clinical study of the application of hAECs to treat POF was also conducted via minimally invasive implantation. The outcomes were measured, including the ovarian volume and hormone levels (NCT03207412).

Investigators performed endoscopic injection of hAECs into bronchial fistula and observed the recovery of bronchial fistula and the resulting systemic reactions (NCT02959333). To evaluate the therapeutic potential of intrathecal hAECs in children with spastic cerebral palsy, functional status and spasticity were evaluated using the modified Ashworth scale (MAS) (NCT03107975). Phase 1/2 clinical trials were designed, in which hAECs were transplanted after debridement, and the efficacy and safety were evaluated for the treatment of non-union fractures (NCT03031509). In allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of leukemia, researchers tried to develop clinically applicable hAEC products and to evaluate their preliminary application in allo-HSCT (NCT03759899). Additionally, a dose escalation study evaluating the safety and efficacy of hAECs in preventing acute graft-versus-host disease after HSCT was conducted (NCT03764228).

In addition, a clinical trial registered by Sievert et al. in the Australian and New Zealand Clinical Trials Registry (ACTRN12616000437460) was conducted to evaluate the safety of intravenously administered hAECs for the treatment of liver fibrosis. In this phase 1 clinical trial, patients who received hAEC transplantation were closely monitored in the first 24 h postinfusion, and long-term follow-up included standard liver tests, transient electography, and hepatic ultrasound [118]. Another study reported that allogeneic hAECs could be safely infused into babies with established bronchopulmonary dysplasia (BPD), and there were no adverse events related to cell administration [119]. Further clinical trials (ACTRN126180009209291) were registered and conducted to evaluate the effectiveness of intravenous hAEC infusion, including a trial to assess the cytokine profile, respiratory outcomes, and neonatal morbidity of infants [120]. In addition, a phase I clinical hAEC therapy of ischemic stroke (ACTRN12618000076279) was designed to determine the maximal tolerated dose (MTD) and assess cell safety. Fifteen stroke patients will be recruited and injected with hAECs by intravenous infusion. Safety and efficacy will be assessed by imaging and immunological assays [121]. These clinical trials will help to determine the safety and clinical benefits of hAEC-based therapy.

Prospects for hAEC-based therapy

The plasticity and therapeutic properties of hAECs are summarized in this review. Enhancing the repair potential of hAECs and achieving precise treatment need to be further considered.

To refine the manufacturing of hAECs and to maximize their capacity to promote functional recovery, there is an increasing need to improve our understanding of the biology and repair mechanism of hAECs. In consideration of special biological characteristics, primary hAECs have been widely used to repair damaged tissues in animal models and preclinical research. However, there are still some bottlenecks, including isolation protocols, EMT process, cell heterogeneity, and measurement methods which hinder the clinical transformation of hAECs [122, 123]. Therefore, establishing a reasonable and optimal isolation protocol and agreeing upon strict definitions for hAECs will be necessary for their future application in tissue regeneration. Second, exploring new biology-guided approaches, including pre-conditioning and genetic manipulation, will facilitate their self-renewal and therapeutic properties of hAECs. For example, a recent study reported that vitamin C promoted the proliferation, migration, and self-renewal of hAECs. Furthermore, hAECs treated with vitamin C showed increased survival after transplantation and secreted a greater amount of growth factors, which improved the therapeutic potential of hAECs in mice with POF [124]. The plant-derived bioactive compound verbenalin significantly increased gene expression in hAECs, contributing to the enhanced neural repair potential of hAECs for AD [125].

On the other hand, paracrine function has been regarded as the main underlying mechanism in hAECs that mediates the recovery of function and immunomodulation; however, many factors can affect the paracrine potential of hAECs. A study revealed that primary and expanded hAECs displayed different differentiation capacity, immunosuppressive property, and paracrine effect, which could be exploited for different cellular therapeutic applications [29]. To enhance the repair potential and facilitate clinical application, some pretreatment approaches need to be further explored. A study showed that prolonged exposure of hAECs to the inflammatory cytokines interferon-gamma (INF-γ) and interleukin-beta (IL-1β) may result in enhanced expression and secretion of immunomodulatory molecules, which are important in treating immune-related diseases [126]. Furthermore, a wide variety of studies should be conducted to validate the potential of hAEC-exosomes, in
which miRNAs and proteins are contained as cargo, and to optimize culture conditions to obtain the optimal secretome with therapeutic value for application.

Currently, combining biomaterials with hAECs has become a novel approach to prolong and strengthen their beneficial effects. Studies have demonstrated that biomaterial scaffolds could contribute to positively modulating the inflammatory response in the tissue and stimulating tissue regeneration. For example, the implantation of hAECs loaded on hydroxyapatite/β-tricalcium phosphate scaffolds not only improved bone regeneration by direct participation but also reduced the early host immune response to the scaffolds [54]. Moreover, biomaterial scaffolds supported hAEC survival and differentiation after transplantation and provided a good microenvironment for tissue regeneration and functional recovery [127]. The latest study reported that poly(lactide-co-glycolide) (PLGA) could be used as a tendon biomimetic fleece for enhancing the differentiation and immunomodulation of transplanted hAECs in injured tendons [128]. Therefore, in vivo and long-term preclinical studies are needed to achieve translation from the bench to the bedside.

Conclusions
Regenerative medicine is a broad field of medicine in which stem cells are used to regenerate the function of injured organs and tissues. hAECs are easy to isolate, have low immunogenicity, and lack ethical concerns; thus, hAECs have extremely important therapeutic potential in regenerative medicine. The current review helps to further explain the different mechanisms of action for hAEC-based cell therapy in treating various diseases. Importantly, the effects of hAEC paracrine function on the injured tissue microenvironment and the maintenance of balance of immunosuppression in recipients were crucial to the process of functional recovery. In the future, enhancing the therapeutic potential and developing new clinical protocols are needed for the application of hAEC-based strategies in regenerative medicine.

Abbreviations
3D: Three-dimensional; AD: Alzheimer’s disease; AGN: Angiogenin; ALP: Alkaline phosphatase; AOD: Autoimmune ovariian disease; BDNF: Brain-derived neurotrophic factor; bFGF: Basic fibroblast growth factor; BMP: Bone morphogenetic protein; BPD: Bronchopulmonary dysplasia; DA: Dopamine; EAE: Experimental autoimmune encephalomyelitis; EAT: Experimental autoimmune thyroiditis; EGF: Epidermal growth factor; EMT: Epithelial to mesenchymal transition; GMP: Good manufacturing procedure; hAEC-CM: Conditioned media of hAECs; hAEC-exosomes: hAEC-derived exosomes; hAECs: Human amniotic epithelial cells; hCECs: Human corneal epithelial cells; HGF: Hepatocyte growth factor; HLA: Human leukocyte antigens; HSC: Hematopoietic stem cell transplantation; HSECs: Hepatic sinusoidal endothelial cells; ICH: Intracerebral hemorrhage; IGF: Insulin-like growth factor; IL-10: Interleukin-10; IL-β: Interleukin-1-beta; IL-5: Interleukin-5; INF-y: Interferon-gamma; iSCs: Insulin secreting cells; LPS: Lipopolysaccharide; LXA4: Lipoxin-A4; MAS: Modified Ashworth scale; miRNAs: MicroRNAs; MMP: Matrix metalloproteinase; MTI: Maximal tolerated dose; NASH: Non-alcoholic steatohepatitis; NGF: Nerve growth factor; NT-3: Neurotrophin-3; OCT-4: Octamer-binding transcription factor-4; OPN: Osteopontin; PBMCs: Peripheral blood mononuclear cells; PD: Parkinson’s disease; PDGFβ: Platelet-derived growth factor β; PDX1: Pancreatic and duodenal homeobox-1; PGE2: Prostaglandin E2; POF: Premature ovarian failure; SAGM: Small airway growth medium; SCS: Schwann-like cells; S-ihCECs: Immortalized human corneal epithelial cells; SLE: Systemic lupus erythematosus; SSEA-3/4: Stage-specific embryonic antigen-3/4; SSM: Substitute serum medium; SSS: Serum substitute supplement; TGF-β: TGF-beta; TRA: Tumor rejection antigen; VEGF: Vascular endothelial growth factor

Acknowledgements
Not applicable

Authors’ contributions
QZ conceived and drafted the manuscript. DL read and approved this manuscript. The author(s) read and approved the final manuscript.

Funding
This work was supported by the National Key Research and Development Program of China (2018YFC1004800 and 2018YFC1004802), the National Natural Science Foundation of China (81701397 and 81971334), the Shanghai Municipal Council for Science and Technology (18410721200 and 20ZR1463200), and the Opening Fund of Key Laboratory of the Diagnosis and Treatment Research of Reproductive Disorders of Zhejiang Province (no. 2018001).

Availability of data and materials
Not applicable

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Received: 1 July 2020 Accepted: 24 September 2020 Published online: 15 October 2020

References
1. Xu H, Zhang J, Tsang KS, Yang H, Gao WQ. Therapeutic potential of human amniotic epithelial cells on injuries and disorders in the central nervous system. Stem Cells Int. 2019;2019:542301.
2. Kim KY, Suh YH, Chang KA. Therapeutic effects of human amniotic epithelial stem cells in a transgenic mouse model of Alzheimer’s disease. Int J Mol Sci. 2020;21(7):2658.
3. Wu ZY, Hui GZ, Lu Y, Wu X, Guo LH. Transplantation of human amniotic epithelial cells improves hindlimb function in rats with spinal cord injury. Chin Med J. 2006;119(24):2101–7.
4. van den Heuij LG, Fraser M, Miller SL, Jenkin G, Wallace EM, Davidson IO, et al. Delayed intranasal infusion of human amnion epithelial cells improves white matter maturation after asphyxia in preterm fetal sheep. J Cereb Blood Flow Metab. 2019;39(2):223–39.
5. He F, Zhou A, Feng S. Use of human amniotic epithelial cells in mouse models of bleomycin-induced lung fibrosis: a systematic review and meta-analysis. PloS One. 2018;13(5):e0197658.
6. Hodges RJ, Lim R, Jenkin G, Wallace EM. Amnion epithelial cells as a candidate therapy for acute and chronic lung injury. Stem Cells Int. 2012;2012:709673.
7. Andrewartha N, Yeoh G. Human amnion epithelial cell therapy for chronic liver disease. Stem Cells Int. 2019;2019:8106482.
8. Lebreton F, Lavallard V, Bellafato K, Bonnet R, Wassmer CH, Perez L, et al. Insulin-producing organoids engineered from iScid and amniotic epithelial cells to treat diabetes. Nat Commun. 2019;10(1):4491.
9. Liu J, Hua R, Gong Z, Shang B, Huang Y, Guo L, et al. Human amniotic epithelial cells inhibit CD4+ T cell activation in acute kidney injury patients by influencing the miR-101-c-Rel-IL-2 pathway. Mol Immunol. 2017;81:76–84.
32. Marongiu F, Gramignoli R, Dorko K, Miki T, Ranade AR, Paola Serra M, et al. Changes in human amniotic epithelial cells cultured in culture expanded human amniotic epithelial cells: implications for potential hepatic differentiation of amniotic epithelial cells. Hepatology. 2011;53(5):1305–13. 

29. Pratama G, Vaghjiani V, Tee JY, Liu YH, Chan J, Tan C, et al. Hepatic differentiation potential of human amniotic epithelial cells. Stem Cells. 2005;23(10):1549–59. 

26. Alcaraz A, Mrowiec A, Insausti CL, Garcia-Vizcaino EM, Ruiz-Canada C, Lopez-Martinez MC, et al. Autocrine TGF-beta induces epithelial to mesenchymal transition in human amniotic epithelial cells. Cell Transplant. 2013;22(8):1351–62. 

23. Gramignoli R, Srinivasan RC, Kannisto K, Strom SC. Isolation of human amniotic epithelial cells from human amnion. J Biosci Bioeng. 2012;114(2):220–7. 

19. Yang PJ, Yuan WX, Liu J, Li JY, Tan B, Qiu C, et al. Biological characterization of cultured human amniotic epithelial cells in serial passages. J Biosci Bioeng. 2012;114(2):220–7. 

16. Miki T. Stem cell characteristics and the therapeutic potential of amniotic epithelial cells. Am J Reprod Immunol. 2018;80(4):e13003. 

13. Li B, Zhang Q, Sun J, Lai D. Human amniotic epithelial cells improve fertility in human amnion epithelial cells. J Biosci Bioeng. 2012;114(2):220–7. 

10. Song YS, Joo HW, Park HJ, Shin GY, Lee Y, Shin JH, et al. Transplanted human amniotic epithelial cells secrete paracrine proangiogenic cytokines in rat model of myocardial infarction. Cell Transplant. 2015;24(10):2055–64. 

11. Zhao B, Liu JQ, Zheng Z, Zhang J, Wang SY, Han SC, et al. Human amniotic epithelial stem cells promote wound healing by facilitating migration and proliferation of keratinocytes via EPK, INK and AKT signaling pathways. Cell Tissue Res. 2016;365(5):855–89. 

12. Zheng X, Jiang Z, Zhou A, Yu L, Quan M, Cheng H. Pathologic changes of wound tissue in rats with stage II pressure ulcers treated by transplantation of human amniotic epithelial cells. Int J Clin Exp Pathol. 2015;8(10):12284–91. 

13. Li B, Zhang Q, Sun J, Lai D. Human amniotic epithelial cells improve fertility in an intraterine adhesion mouse model. Stem Cell Res Ther. 2019;10(1):257. 

14. Zhang Q, Xu M, Yao X, Li T, Wang Q, Lai D. Human amniotic epithelial cells inhibit granulosa cell apoptosis induced by chemotherapy and restore the fertility. Stem Cell Res Ther. 2015;6:152. 

15. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005;23(10):1549–59. 

16. Miki T. Stem cell characteristics and the therapeutic potential of amniotic epithelial cells. Am J Reprod Immunol. 2018;80(4):e13003. 

17. Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod. 2007;77(3):577–88. 

18. Wassmer CH, Berishvili E. Immunomodulatory properties of amniotic membrane derivatives and their potential in regenerative medicine. Curr Diab Rep. 2020;20(8):31. 

19. Yang P, Yuan WX, Liu J, Li JY, Tan B, Qiu C, et al. Biological characterization of human amniotic epithelial cells in a serum-free system and their safety evaluation. Acta Pharmacol Sin. 2018;39(8):1305–16. 

20. Trosan P, Smeringerova I, Brejchova K, Bednar J, Benada O, Kofronova O, et al. The enzymatic de-epithelialization technique determines denuded amniotic membrane integrity and viability of harvested epithelial cells. PLoS One. 2018;13(3):e0194820. 

21. Tabatabaei M, Mosaffa N, Nikoo S, Bozorgmehr M, Ghods R, Kazemejnad S, et al. Isolation and partial characterization of human amniotic epithelial cells: the effect of trypsin. Avicenna J Med Biotechnol. 2014;6(1):10–20. 

22. Motedayen H, Esmaeil N, Tajik N, Khadem F, Ghotloo S, Khanbi B, et al. Method and key points for isolation of human amniotic epithelial cells with high yield, viability and purity. BMC Res Notes. 2017;10(1):552. 

23. Gasmioglu R, Sinivasan RC, Kannisto K, Strom SC. Isolation of human amnion epithelial cells according to current good manufacturing procedures. Curr Protoc Stem Cell Biol. 2016;53:17.1-10-1-13. 

24. Fatimah SS, Tan GC, Chua KH, Tan AE, Hayati AR. Effects of epithelial growth factor on the proliferation and cell cycle regulation of cultured human amnion epithelial cells. J Biosci Bioeng. 2012;114(2):220–7. 

25. Simat SF, Chua KH, Abdul Rahman H, Tan AE, Tan GC. The stemness gene expression of cultured human amniotic epithelial cells in serial passages. Med J Malaysia. 2008;63(Suppl A):153–4. 

26. Alcaraz A, Mrowiec A, Insauti CL, Garcia-Vizcaino EM, Ruiz-Cana D, Lopez-Martinez MC, et al. Autocrine TGF-beta induces epithelial to mesenchymal transition in human amniotic epithelial cells. Cell Transplant. 2013;22(8):1351–67. 

27. Janzen C, Sen S, Lei MY, Gagliardi de Assumpcao M, Chailis J, Chaudhuri G. The role of epithelial to mesenchymal transition in human amniotic membrane rupture. J Clin Endocrinol Metab. 2017;102(6):1261–9. 

28. Evron A, Goldman S, Shalev E. Human amniotic epithelial cells cultured in substitute serum medium maintain their stem cell characteristics for up to four passages. Int J Stem Cells. 2011;4(2):123–32. 

29. Pratama G, Vaghjiani V, Tey JJ, Liu YH, Chan J, Tan C, et al. Changes in culture expanded human amniotic epithelial cells: implications for potential therapeutic applications. PLoS One. 2011;6(11):e26136. 

30. Easley CA, Miki T, Castro CA, Ozaktar J, Minervini CF, Ben-Yehuda A, et al. Human amniotic epithelial cells are reprogrammed more efficiently by induced pluripotency than adult fibroblasts. Cell Reprogram. 2012;14(3):193–203. 

31. Luo H, Huang X, Huang F, Liu X. Transplanted human amniotic epithelial cells into hepatocele-like cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(6):525–31. 

32. Marongiu F, Gramignoli R, Dorico K, Miki T, Randaré AR, Paola Serra M, et al. Hepatic differentiation of amniotic epithelial cells. HEPATOLOGY. 2011;53(5):1719–29. 

33. Maymo JL, Riedel R, Perez-Perez A, Magatti M, Maskin B, Duenas JL, et al. Proliferation and survival of human amniotic epithelial cells during their hepatic differentiation. PLoS One. 2018;13(1):e0191489.
56. Luan F, Ma K, Mao J, Yang F, Zhang M, Luan H. Differentiation of human amniotic epithelial cells into osteoblasts is induced by mechanical stretch via the Wnt/betacatenin signalling pathway. Mol Med Rep. 2018;18(6):5717–25.

57. Murphy SV, Lim R, Herraud P, Chelewa M, Le Gros M, de Jonge MD, et al. Human amniotic epithelial cells induced to express functional cystic fibrosis transmembrane conductance regulator. PLoS One. 2012;7(9):e46533.

58. Han X, Wan Q, Wu W, Zheng A, Li L, Liu J, Xu A. Activin A and BMP-4 induce cardiomyocyte-like cells differentiation of human amniotic epithelial cells. Sheng Wu Yi Xue Gong. Xue Zhe. 2011;28(6):1217–22.

59. Fatimah SS, Chua K, Tan GC, Azmi TI, Tan AE, Abdul RH. Organotypic culture of human amnion cells in air-liquid interface as a potential substitute for skin regeneration. Cytotherapy. 2013;15(8):1030–41.

60. Kakikita K, Elwan MA, Nakao N, Ikataku T, Sakuragawa N. Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of Parkinson’s disease: a potential source of donor for transplantation therapy. Exp Neurol. 2000;165(1):27–34.

61. Liu T, Wu J, Huang Q, Hou Y, Jiang Z, Zang S, et al. Human amniotic epithelial cells ameliorate behavioral dysfunction and reduce infarct size in the rat middle cerebral artery occlusion model. Shock. 2008;29(3):603–11.

62. Xue SR, Chen CT, Dong WL, Hui GZ, Liu TJ, Guo LH. Intracerebroventricular transplantation of human amniotic epithelial cells ameliorates spatial memory deficit in the double transgenic mouse coexpressing APPswpe and PS1DeltaE9-deleted genes. Chin Med J. 2011;124(17):2642–8.

63. Hodges RJ, Jenkins G, Hooper SB, Allison B, Lim R, Dickinson H, et al. Human amniotic epithelial cells reduce ventilation-induced pretterm lung injury in the sheep. Am J Obstet Gynecol. 2012;206(5):e1–14.

64. Zhang NN, Huang GL, Han QB, Hu X, Yi J, Yao L, et al. Functional regeneration of irradiated salivary glands with human amniotic epithelial cells transplantation. Int J Clin Exp Pathol. 2013;6(10):2039–47.

65. Yuge I, Takuoki Y, Koyabu K, Hashimoto T, Sotokura K, Fukuyama T, et al. Transplanted human amniotic epithelial cells express connexin 26 and Na-K-adenosine triphosphatase in the inner ear. Transplantation. 2004;77(9):1452–4.

66. Barboni B, Russo V, Gatta V, Bernardo N, Berardinelli P, Mauro A, et al. Therapeutic potential of hAECs for early Achilles tendon defect repair through regeneration. J Tissue Eng Regen Med. 2018;12(3):e1594–e608.

67. Wu Z, Hui G, Liu Y, Li T, Huang Q, Guo L. Human amniotic epithelial cells express specific markers of nerve cells and migrate along the nerve fibers in the corpus callosum. Neurogenn Res. 2013;7(1):141–5.

68. Evans MA, Lim R, Kim HA, Chiu HX, Gardiner-Mann CV, Taylor KWE, et al. Acute or delayed systemic administration of human amniotic epithelial cells improves outcomes in experimental stroke. Stroke. 2018;49(2):121–32.

69. Zhao B, Zhang Y, Han S, Zhang W, Zhou Q, Guan H, et al. Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation. J Mol Histol. 2017;48(2):121–32.

70. Zhao B, Wu GF, Zhang Y, Zhang W, Yang F, Xiao D, et al. Effects of human amniotic epithelial stem cells-derived exosomes on healing of wound with full-thickness skin defect in rats. Zhejiang Shao Shao Zhe Zhi. 2013;23(3):18–23.

71. Zhang W, Li X, Shi X, Shi X, Zhang W, Wu G, et al. Exosomal microRNAs derived from human amniotic epithelial cells accelerate cell wound healing by promoting the proliferation and migration of fibroblasts. Stem Cells Int. 2018;2018:542063.

72. Tan JL, Lau SN, Leaw B, Nguyen HPT, Salamonsen LA, Saad MI, et al. Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair. Stem Cells Transl Med. 2018;7(2):180–96.

73. Zhang Q, Sun J, Huang Y, Bu S, Guo Y, Guo T, et al. Human amniotic epithelial cell-derived exosomes restore ovarian function by transferring microRNAs against apoptosis. Mol Ther Nucleic Acids. 2019;16:407–17.

74. Hodge A, Lourenzis D, Vaghjiani V, Nguyen H, Tchongue J, Wang B, et al. Soluble factors derived from human amniotic epithelial cells suppress collagen production in human hepatic stellate cells. Cytotherapy. 2014;16(8):1132–44.

75. Lim R, Chan ST, Tan J, Mollcrck J, Murphy SV, Wallace EM. Preterm human amniotic epithelial cells have limited reparative potential. Placenta. 2013;34(6):486–92.

76. Zhu D, Muljadi R, Chan ST, Vodosegan P, Lo C, Mollcrck J, et al. Evaluating the impact of human amnion epithelial cells on angiogenesis. Stem Cells. 2016;2016:456512.

77. Prathipati P, Nandi SS, Mishra PK. Stem cell-derived exosomes, autophagy, extracellular matrix turnover, and miRNAs in cardiac regeneration during stem cell therapy. Stem Cell Rev Rep. 2017;13(1):79–91.

78. Yuan KM, Zhang PH, Qi SS, Zhu QZ, Li P. Emerging role for exosomes in the treatment of experimental autoimmune encephalomyelitis. J Neuroinflammation. 2015;12:112.

79. Magatti M, Caruso M, De Munari S, Vertua E, De D, Manuellilalli U, et al. Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocytic derived dendritic cell differentiation and function. Cell Transplant. 2015;24(9):1733–52.

80. Kozumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. Curr Eye Res. 2002;20(3):173–7.

81. Motedayyen H, Zamani AH, Taji K, Nghosto S, Rezaei A. Immunomodulatory effects of human amniotic epithelial cells on naive CD4(+) T cells from women with unexplained recurrent spontaneous abortion. Placenta. 2018;71:31–40.

82. Motedayyen H, Rezaei A, Zamani AH, Taji K. Human amniotic epithelial cells inhibit activation and proinflammatory cytokines production of naive CD4(+) T cells from women with unexplained recurrent spontaneous abortion. Reprod Biol. 2018;18(2):182–8.

83. Alipour R, Motedayyen H, Sereshki N, Rafeie M, Alshehlaosif S, Pourazar A. Human amniotic epithelial cells affect the functions of neutrophils. Int J Stem Cells. 2020;13(2):212–20.
